Acting from the heart: Behavior and cognitive function of rats with heart failure with preserved ejection fraction and empagliflozin effects
Our project aims to characterize a cardiometabolic animal model of Heart Failure with Preserved Ejection Fraction (HFpEF) in terms of behavior and cognitive function and to evaluate the impact of empagliflozin, an SGLT2 inhibitor used in HFpEF treatment. We used a well-accepted animal model of HFpEF, mimicking its metabolic and cardiovascular features – ZSF1‐Obese and ZSF1‐Lean rats as corresponding controls. At the first signs of diastolic dysfunction, half of the ZSF1- Obese and Lean rats were randomly assigned to treatment with empagliflozin administered through diet. 24-week-old animals we